Difference between revisions of "Team:Edinburgh/Sponsors"
| (6 intermediate revisions by the same user not shown) | |||
| Line 7: | Line 7: | ||
<script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.5/js/bootstrap.min.js"></script> | <script src="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.5/js/bootstrap.min.js"></script> | ||
</head> | </head> | ||
| − | + | <!-- menu --> | |
<div id="custom-bootstrap-menu" class="navbar navbar-default navbar-fixed-top" role="navigation"> | <div id="custom-bootstrap-menu" class="navbar navbar-default navbar-fixed-top" role="navigation"> | ||
<div class="container-fluid"> | <div class="container-fluid"> | ||
| Line 36: | Line 36: | ||
<li><a href="https://2015.igem.org/Team:Edinburgh/DNPBiosensor">DNP Biosensor</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/DNPBiosensor">DNP Biosensor</a></li> | ||
<li><a href="https://2015.igem.org/Team:Edinburgh/PMABiosensor">PMA Biosensor</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/PMABiosensor">PMA Biosensor</a></li> | ||
| − | <li><a href="https://2015.igem.org/Team:Edinburgh/CBD">Making it Stick</a></li> | + | <li><a href="https://2015.igem.org/Team:Edinburgh/CBD">Making it Stick</a></li> |
| − | <li><a href="https://2015.igem.org/Team:Edinburgh/Results"> | + | <li><a href="https://2015.igem.org/Team:Edinburgh/Results">Limits of Detection</a></li> |
</ul> | </ul> | ||
</li> | </li> | ||
| Line 43: | Line 43: | ||
<a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">Parts<span class="caret"></span></a> | <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">Parts<span class="caret"></span></a> | ||
<ul class="dropdown-menu" role="menu"> | <ul class="dropdown-menu" role="menu"> | ||
| − | + | <li><a href="https://2015.igem.org/Team:Edinburgh/Parts">Team Parts</a></li> | |
<li><a href="https://2015.igem.org/Team:Edinburgh/Basic_Part">Basic Parts</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/Basic_Part">Basic Parts</a></li> | ||
<li><a href="https://2015.igem.org/Team:Edinburgh/Composite_Part">Composite Parts</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/Composite_Part">Composite Parts</a></li> | ||
| − | + | <li><a href="https://2015.igem.org/Team:Edinburgh/Part_Collection">Part Collection</a> </li> | |
<li><a href="https://2015.igem.org/Team:Edinburgh/Improved_Part">Improved Parts</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/Improved_Part">Improved Parts</a></li> | ||
<li><a href="https://2015.igem.org/Team:Edinburgh/Characterisation_Part">Improved Characterisation</a></li> | <li><a href="https://2015.igem.org/Team:Edinburgh/Characterisation_Part">Improved Characterisation</a></li> | ||
| Line 85: | Line 85: | ||
</ul> | </ul> | ||
</li> | </li> | ||
| − | <li><a href="https://2015.igem.org/Team:Edinburgh/MedalCriteria"> | + | <li><a href="https://2015.igem.org/Team:Edinburgh/MedalCriteria">Accomplishments</a></li> |
</ul> | </ul> | ||
</div> | </div> | ||
</div> | </div> | ||
</div> | </div> | ||
| + | |||
| Line 105: | Line 106: | ||
<h1 class="brand-heading">Sponsors</h1> | <h1 class="brand-heading">Sponsors</h1> | ||
<p class="intro-text"> | <p class="intro-text"> | ||
| + | |||
</p> | </p> | ||
<div align="center"> | <div align="center"> | ||
| Line 122: | Line 124: | ||
<div class="container"> | <div class="container"> | ||
<div class="row"> | <div class="row"> | ||
| − | <div class=" | + | <div align="center"> |
| + | <p> | ||
| + | This iGEM team has been funded by the MSD Scottish Life Sciences Fund. As part of an ongoing contribution to Scottish life sciences, MSD Limited, a global healthcare leader has given substantial monetary funding to the Scottish Funding Council (SFC) for distribution via the Scottish Universities Life Sciences Alliance (SULSA) to develop and deliver a high quality drug discovery research and training programme. All aspects of the programme have been geared towards attaining the highest value in terms of scientific discovery, training and impact. The opinions expressed by this iGEM team are those of the team members and do not necessarily represent those of Merck Sharp&Dohme Limited nor its Affiliates. | ||
| + | </p> | ||
| + | |||
| + | <img class="img-responsive" src="https://static.igem.org/mediawiki/2015/c/cb/Edigem15_MSDLogo.png"> | ||
| + | <br> | ||
| + | <br> | ||
| + | <br> | ||
<img class="img-responsive" src="https://static.igem.org/mediawiki/2015/f/f4/Edigem15_sponsors.png"> | <img class="img-responsive" src="https://static.igem.org/mediawiki/2015/f/f4/Edigem15_sponsors.png"> | ||
</div> | </div> | ||
Latest revision as of 19:01, 20 November 2015
This iGEM team has been funded by the MSD Scottish Life Sciences Fund. As part of an ongoing contribution to Scottish life sciences, MSD Limited, a global healthcare leader has given substantial monetary funding to the Scottish Funding Council (SFC) for distribution via the Scottish Universities Life Sciences Alliance (SULSA) to develop and deliver a high quality drug discovery research and training programme. All aspects of the programme have been geared towards attaining the highest value in terms of scientific discovery, training and impact. The opinions expressed by this iGEM team are those of the team members and do not necessarily represent those of Merck Sharp&Dohme Limited nor its Affiliates.
